Lucy Scientific Discovery Inc. Unveils New Sleep Aid Product: Twilight by Lucy
11 Julio 2023 - 8:00AM
Lucy Scientific Discovery Inc. (NASDAQ: LSDI), an innovator in
psychotropic drug development, proudly announces the launch of
"Twilight" – a blend of Amanita and Reishi mushrooms that include a
variety of other nootropics promoting improved cognitive function
and enhanced sleep quality. This release comes on the heels of the
recent launch of "Mindful" by Lucy. Both of these products are now
available for purchase on the company's official online store,
www.buytrippy.com, as well as through Hightimes.com and other
channels.
Twilight by Lucy is a product designed to enhance and optimize
consumer’s nightly sleep. The introduction of Twilight alongside
Mindful underscores Lucy Scientific Discovery's dedication to
providing solutions in the psychotropic marketplace.
"We are incredibly excited to present Twilight to our customers,
and offer them a nightly solution for improved sleep," stated
Chanel Perez, Director of Marketing of Lucy Scientific Discovery
Inc. "Sleep disorders, a pervasive issue faced by a significant
proportion of the population, can significantly affect one's
overall well-being. After the encouraging reception of Mindful by
Lucy, we are confident that Twilight will follow its success and
enhance the lives of our customers."
According to the National Heart, Lung, and Blood Institute, it
is estimated that around 50 to 70 million adults in the United
States suffer from sleep disorders. This represents approximately
15-20% of the adult population in the country. Additionally, the
global sleep aids market is projected to grow to $125.3 billion in
2027.
The current formulations are available in capsule form, but will
be made available in other formats in the near future.
To learn more about Twilight by Lucy and unlock the
transformative power of better sleep, visit the company's official
Direct to Consumer platform at www.buytrippy.com/twilight.
About Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is a Nasdaq-listed
company and a licensed producer of compounds for medicinal
products. Holding a Controlled Drugs and Substances Dealer's
License granted by Health Canada's Office of Controlled Substances,
Lucy Scientific Discovery Inc. and its wholly-owned subsidiary,
LSDI Manufacturing Inc., operate under Part J of the Food and Drug
Regulations promulgated under the Food and Drugs Act (Canada). This
specialized license authorizes LSDI to develop, sell, deliver, and
manufacture pharmaceutical-grade active pharmaceutical ingredients
(APIs) used in controlled substances and their raw material
precursors. Lucy does not sell psilocybin products to the general
public. With a focus on pioneering innovative therapies for
patients in need, Lucy Scientific Discovery Inc. is dedicated to
advancing the understanding and applications of psychedelic
medicine, improving mental health outcomes, and enhancing
well-being for individuals worldwide.
Cautionary Note Regarding Forward-Looking
Statements
This press release may contain forward-looking statements.
Forward-looking statements give our current expectations or
forecasts of future events. You can identify these statements by
the fact that they do not relate strictly to historical or current
facts. Forward-looking statements involve risks and uncertainties
and include statements regarding, among other things, our projected
revenue growth and profitability, our growth strategies and
opportunity, anticipated trends in our market and our anticipated
needs for working capital. They are generally identifiable by use
of the words "may," "will," "should," "anticipate," "estimate,"
"plans," "potential," "projects," "continuing," "ongoing,"
"expects," "management believes," "we believe," "we intend" or the
negative of these words or other variations on these words or
comparable terminology. In particular, these include statements
relating to future actions, prospective products, market
acceptance, future performance, results of current and anticipated
products, sales efforts, expenses, and the outcome. Most of these
factors are outside Lucy’s control and are difficult to predict.
Factors that may cause actual future events to differ materially
from the expected results, include, but are not limited to: (i) the
occurrence of any event, change or other circumstance that could
give rise to the legality of this consumer product , (ii)
inability to recognize the anticipated benefits of the opportunity,
which may be affected by, among other things, competition and the
ability of the company to grow and manage growth profitability,
(iii) costs related to the production, (iv) the ability to
implement business plans, forecasts, and other expectations of the
opportunity, as well as identify and realize additional
opportunities, (v) the outcome of any legal proceedings that may be
instituted against Lucy following the announcement of the new
product line, and (vi) other risks and uncertainties indicated in
the filings that are made from time to time with the SEC by Lucy
(including those under the “Risk Factors” sections therein).
These statements are based on our management's expectations,
beliefs and assumptions concerning future events affecting us,
which in turn are based on currently available information. These
assumptions could prove inaccurate. Although we believe that the
estimates and projections reflected in the forward-looking
statements are reasonable, our expectations may prove to be
incorrect.
Investor Contact:Addo Investor Relations,
Inc.lucyscientific@addo.com
Lucy Scientific Discovery (NASDAQ:LSDI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lucy Scientific Discovery (NASDAQ:LSDI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024